美國Mineralocorticoid(f-hMR) 人鹽皮質**受體可誘導表達細胞株
美國PrimCells誘導性穩定細胞株： PrimCells建立的獨有的誘導性細胞高效開發系統，能在極短時間內篩選出低泄漏，高誘導性的穩定細胞株，成功開發出一系列核受體誘導表達的穩定細胞株產品，為多家知名制藥公司研發部門和科研院所提供產品與服務，廣受用戶好評。針對客戶的特定需求，PrimCells亦提供量身定制服務，通過密切的客戶交流和高效的篩選體系，嚴格保證客戶在3-4周內即獲得高質量的誘導性穩定細胞株，具有市場其他供應商無可比擬的時效性。
Introduction:
Nuclear hormone receptors (NHRs) are a superfamily of transcription factors that function as powerful metabolic regulators to control a variety of systemic processes in physiology. They also play key roles in the pathophysiology of many major disease states, such as diabetes, obesity, inflammation, atherosclerosis and heart failure. To date, this superfamily has provided a rich source of drug design targets and it is continuing to be one of the hottest areas for pharmaceutical research. PrimCells now provides a comprehensive set of NHR expressing cell lines to the research community. These high-quality, flag- and/or HA-tagged NHR-expressing cell lines aim to facilitate further biochemical and molecular studies of their functions and hence encourage new strategies for drug design.
f-hMR/HEK293 cell line was created by stable co-transfection of HEK293 cells with two plasmids expressing the bacterial Tet repressor (TetR) and the human mineralocorticoid receptor (hMR) proteins. Since the hMR gene is driven by a promoter containing two tetracycline operator (TeTO2) sites, the expression of hMR protein can be induced by doxycycline.
Figure 1 | Confirmed hMR Expression in f-hMR stable cells
美國PrimCells品牌介紹
PrimCells是位于美國加州圣迭戈的一家專業致力于細胞產品研發和解決方案提供的業內技術領導企業。
公司匯集了**的生物醫藥技術專家，獨立開發了多項原代細胞和干細胞相關的專有技術。 公司以“細胞研究的選擇”為宗旨，自主研發超過70種**產品，填補了多個特種細胞市場的空白。例如其誘導性表達細胞庫和高效3D皮膚培養系統，皆為該類產品目前市場上少數的規?；?。此外，公司以高質量的數據與快速穩定的項目完成時間，長期為多家知名制藥公司提供解決方案，獲得用戶廣泛贊譽。
PrimCells產品線：
-
報告基因干細胞 2. 原代細胞（含報告基因原代細胞） 3. 誘導性穩定細胞株
4. 人源重組蛋白 5. **型培養試劑
PrimCells 解決方案
1.誘導性穩定細胞株開發 2. 原代細胞開發 3. **體外毒理和效能測試 4. 3D-皮膚培養
PrimCells合作伙伴及客戶:
A．生物制藥公司：輝瑞(Pfizer), 諾華(Novartis), 禮來(Eli2 Lilly),. Amgen, EMD Millipore, Regeneron等公司的毒理和醫藥研發部門
B．科研機構：冷泉港實驗室，哈佛醫學院, 麻省理工（MIT）,， UCSF, NYU, Salk, UIUC, USC等
